Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement

Executive Summary

• Appili Therapeutics closed the second tranche of its non‑brokered private placement, raising C$100,000.
• The placement issued 4,000,000 units at C$0.025 per unit, each unit consisting of one Class A common share and half a warrant to purchase an additional share at C$0.05 (exercisable for 36 months pending shareholder approval).
• Net proceeds will be used primarily for working capital and the development of the company’s product candidates.

Key Details

• Units sold: 4,000,000 units @ C$0.025 per unit → gross proceeds C$100,000.
• Unit composition: 1 Class A common share + ½ Common Share purchase warrant (full warrant allows purchase of one share at C$0.05).
• Warrant terms: Exercisable for 36 months from closing date, subject to shareholder approval sought by the next Annual General Meeting; otherwise non‑exercisable.
• Broker Warrants: Paid finders C$8,000 and issued 320,000 broker warrants at a minimum price of C$0.02834 per share, exercisable for 24 months pending the same shareholder approval.
• Use of proceeds: Primarily working capital and funding development of selected product candidates.
• Statutory hold period: All securities subject to a four‑month‑plus‑one‑day hold period from issuance date.
• Future updates: Company will provide updates on any additional closings under the private placement.

Notable Quotes

(No direct quotes were included in the release.)